Creating tumor models to test new cancer treatments

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study collects tumor samples from patients with specific mutations to develop spheroid cell cultures. These spheroids will be used to model how tumors respond to various anticancer therapies. By testing different therapeutic molecules on these spheroids, researchers aim to evaluate the effectiveness of new and existing treatments tailored to the patient's tumor characteristics. Tumor samples will be obtained through routine biopsies or surgeries.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older.
* Patient for whom at least one mutation deemed of interest by the investigator has been identified.
* Patient with a malignant tumor at a locally advanced or metastatic stage, for whom a tissue tumor sample (via surgery, radiology, or endoscopy) is scheduled as part of their standard care.
* Tumor volume deemed sufficient by the physician to ensure an adequate amount of material for analysis by the pathologist and the transfer of a part of the tumor sample to the Laboratory of Translational Research in Oncology for the study.
* INR \< 1.5; Platelets \> 50,000/μL.
* Patient who has been informed of the study and has signed the informed consent form.
* Patient affiliated with a social security insurance.

Exclusion Criteria:

* Patient with multiple primary malignant tumors.
* Patient with a known HIV, Hepatitis C, or Hepatitis B infection.
* Patient on:

  * Clopidogrel (hydrogensulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) with no possibility of suspension for 5 days,
  * Low molecular weight heparin with no possibility of dose suspension before the procedure,
  * Fondaparinux with no possibility of suspension,
  * Abciximab with no possibility of suspension for 24 hours and aPTT \< 50s and ACT \< 150s,
  * Eptifibatide or Tirofiban Hydrochloride Monohydrate or Argatroban with no possibility of suspension 4 hours before the procedure,
  * Bivalirudin with no possibility of suspension 2-3 hours if CrCL \>50 mL/min or 3-5 hours if CrCL \<50 mL/min before the procedure,
  * Dabigatran etexilate with no possibility of suspension 2-3 days if CrCL \>50 mL/min or 3-5 days if CrCL \<50 mL/min before the procedure.
* Patient considered vulnerable; vulnerable persons are defined in articles L1121-5 to L1121-8:

  * Pregnant women, parturients, and breastfeeding mothers,
  * Individuals deprived of their liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and individuals admitted to a healthcare or social facility for reasons other than research,
  * Adults under legal protection or unable to express their consent.

Where it's running

• Centre Antoine Lacassagne
  Nice, France Recruiting

Study contacts

• Study coordinator: Study coordinator
• Email: DRCI-Promotion@nice.unicancer.fr
• Phone: +33 04 92 03 14 76

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Calderasib (MK-1084) with or without cetuximab for advanced KRAS G12C solid tumors

  This study will test whether calderasib (MK-1084), alone or combined with cetuximab, can shrink advanced solid tumors in people whose cancers have the KRAS G12C mutation.

  Recruiting at 71 sites Phase 2 Merck Sharp & Dohme LLC · Baltimore, Maryland and 71 other locations · NCT07209111

• Evaluating liquid biopsy for cancer diagnosis

  This study tests if a blood test that looks for cancer DNA can help doctors find problems in patients with advanced cancer, comparing it to the usual tissue tests.

  Recruiting Centre Antoine Lacassagne · Nice · NCT06606366

• Observing cancer outcomes in patients receiving integrative oncology care

  This study is testing how well combining naturopathic medicine with regular cancer treatments helps early-stage and advanced-stage cancer patients live longer and stay healthy.

  Recruiting Advanced Integrative Medical Science Institute · Seattle, Washington · NCT04495790

• Using a virus therapy to treat recurrent cerebellar brain tumors in children

  This study is testing a new virus treatment for children with recurring brain tumors to see if it can help them get better when combined with a low dose of radiation.

  Recruiting at 3 sites Phase 1 M.D. Anderson Cancer Center · Birmingham, Alabama and 2 other locations · NCT03911388

• Exploring the link between body weight and quality of life in cancer patients

  This study is trying to see how body weight affects the quality of life for adults with solid tumors, like breast or lung cancer.

  Recruiting University of Rome Tor Vergata · Rome · NCT03873064

• See if virtual informed consent methods help people decide to join cancer research

  This trial tests whether virtual human communicators and different consent messages can influence cancer patients’ understanding and willingness to participate in research.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT07805083

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.